Comparative Pharmacology
Head-to-head clinical analysis: FURALAN versus HIPREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURALAN versus HIPREX.
FURALAN vs HIPREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Hippuric acid, the active metabolite of methenamine, acidifies urine and releases formaldehyde, which denatures bacterial proteins and nucleic acids, bactericidal activity requires acidic urine (pH < 5.5).
20 mg orally three times daily for 7 days.
1 gram orally twice daily (every 12 hours) with meals
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
3-6 hours (methenamine); clinical context: prolonged in renal impairment, requiring dose adjustment.
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Renal excretion: >90% as unchanged drug (methenamine) and formaldehyde; biliary/fecal: <5%.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective